Verrica Pharmaceuticals Inc.
VRCA
$6.11
-$0.04-0.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -64.50% | 12.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -64.50% | 12.93% | |||
| Cost of Revenue | 18.32% | 41.62% | |||
| Gross Profit | -89.38% | 6.45% | |||
| SG&A Expenses | -13.68% | 6.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.34% | 13.63% | |||
| Operating Income | -526.92% | 7.75% | |||
| Income Before Tax | -2,846.72% | -234.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2,846.72% | -234.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2,846.72% | -234.31% | |||
| EBIT | -526.92% | 7.75% | |||
| EBITDA | -493.32% | 6.24% | |||
| EPS Basic | -1,879.93% | -234.42% | |||
| Normalized Basic EPS | -1,448.89% | -234.33% | |||
| EPS Diluted | -1,879.93% | -244.50% | |||
| Normalized Diluted EPS | -1,448.89% | -234.33% | |||
| Average Basic Shares Outstanding | 48.68% | 0.02% | |||
| Average Diluted Shares Outstanding | 48.68% | -0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||